The cervical solution marks the completion of
the NuVasive Reline fixation portfolio for complex deformity from
occiput to sacrum
SAN
DIEGO, Sept. 28, 2022 /PRNewswire/ -- NuVasive,
Inc. (NASDAQ: NUVA), the leader in spine technology innovation,
focused on transforming spine surgery with minimally disruptive,
procedurally integrated solutions, announced today the commercial
launch of Reline® Cervical, a new fixation system for
posterior cervical fusion (PCF), in targeted regions.
![NuVasive Logo NuVasive Logo](https://mma.prnewswire.com/media/454552/NuVasive_Logo.jpg)
"Reline Cervical completes the foundational three strategic
pillars of C360™—anterior cervical decompression and fusion,
cervical total disc replacement, and now PCF. This launch is a
significant step forward for our fixation portfolio and furthers
our goal of becoming the market leader in complex deformity while
extending our position with the industry's leading cervical
portfolio," said Ryan Donahoe, chief technology officer
at NuVasive. "We have leveraged our expertise with the proven
Reline system, combined with Pulse®, to deliver our best
PCF solution. The key advancements in this procedural technology
fuel continued growth and differentiation in the cervical spine
segment."
As cervical spine procedures comprise an approximately $2.6
billion subsegment of the global spine market, the
introduction of Reline Cervical will allow the Company's C360
portfolio to take even more share. Surgeons can address complex PCF
surgeries within one comprehensive fixation portfolio, as well as
utilize the enabling technologies within Pulse. The compatibility
of Reline Cervical with Pulse gives surgeons the benefits of
navigation, imaging enhancement, intraoperative neuromonitoring,
iGA®, and patient-specific rod bending.
"The Reline Cervical design is best-in-class. I'm impressed by
the screw range, great connector options, and the full junctional
offering, helping me address the varying complex deformity cases I
see in my practice," said Steven Ludwig, M.D., orthopedic
spine surgeon at the University of Maryland. "Having the
benefits of the thoracolumbar Reline system now in the cervical
spine gives me confidence that I'm giving my patients the best
solution."
The expansion of the C360 portfolio further supports a
comprehensive anterior and posterior offering of instrumentation,
implants, biologic materials, and enabling technologies for any
cervical procedure.
NuVasive will feature its C360 portfolio at these upcoming
2022 events:
- NuVasive Innovation Event: On November 16, join NuVasive virtually to
hear Company leadership and surgeon partners
discuss all comprehensive procedural portfolios—X360, C360,
thoracolumbar posterior, posterior fixation, pediatrics, and the
enabling technologies within Pulse. Hear from surgeons on the
Reline Cervical system and how it has already made an impact on
their practices.
- 50th Cervical Spine Research Society Annual
Meeting: From November 16 to
19, visit NuVasive at booth #105/204 to see the full
C360 portfolio—Reline Cervical, the
Simplify® Cervical Disc, the NuVasive anterior
cervical plate system, cervical Advanced Materials
Science® interbody implants, and Pulse.
Reline Cervical is available in the U.S. The timeline for
availability in other markets cannot be guaranteed.
About NuVasive
NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine
technology innovation, with a mission to transform surgery, advance
care, and change lives. The Company's less-invasive, procedurally
integrated surgical solutions are designed to deliver reproducible
and clinically proven outcomes. The Company's comprehensive
procedural portfolio includes surgical access instruments, spinal
implants, fixation systems, biologics, software for surgical
planning, navigation and imaging solutions, magnetically adjustable
implant systems for spine and orthopedics, and intraoperative
neuromonitoring technology and service offerings. With more
than $1 billion in net sales, NuVasive operates
in more than 50 countries serving surgeons, hospitals, and
patients. For more information, please
visit www.nuvasive.com.
Forward-Looking
Statements
NuVasive cautions you that statements included in this news
release that are not a description of historical facts are
forward-looking statements that involve risks, uncertainties,
assumptions and other factors which, if they do not materialize or
prove correct, could cause NuVasive's results to differ
materially from historical results or those expressed or implied by
such forward-looking statements. The potential risks and
uncertainties which contribute to the uncertain nature of these
statements include, among others, risks associated with acceptance
of the Company's surgical products and procedures by spine surgeons
and hospitals, development and acceptance of new products or
product enhancements, clinical and statistical verification of the
benefits achieved via the use of NuVasive's products, the
Company's ability to adequately manage inventory as it continues to
release new products, its ability to recruit and retain management
and key personnel, and the other risks and uncertainties described
in NuVasive's news releases and periodic filings with
the Securities and Exchange
Commission. NuVasive's public filings with
the Securities and Exchange Commission are available at
www.sec.gov. NuVasive assumes no obligation to update any
forward-looking statement to reflect events or circumstances
arising after the date on which it was made.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nuvasive-launches-reline-cervical-for-posterior-cervical-fusion-as-part-of-the-c360-portfolio-301635108.html
SOURCE NuVasive, Inc.